Skip to main content
SpringerLink
Log in

Modern Radiotherapy in Limited and Extensive Stage Small-Cell Lung Cancer

  • Chapter
  • First Online:
Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies

  • 1108 Accesses

Abstract

Small-cell lung cancer (SCLC) represents for approximately 10–15 % all lung cancers. Typically, SCLC presents in senior patients (>70 years) with a substantial smoking history. According to historic Veteran’s Administration Lung Study Group staging criteria, SCLC is simply divided into two respective stages: limited stage (LS-SCLC) and extensive stage SCLC (ES-SCLC). Despite fundamental improvements in imaging and treatment modalities, prognosis of SCLC patients is still poor with median survival ranges of only 15–20 months for LS-SCLC and 8–13 months for ES-SCLC. Unless diagnosed quite early, which constitutes only less than 5 % of all SCLC patients, surgery currently has little or almost no role in the standard management of SCLC. Therefore, surgery is recommended for only medically fit stage I SCLC patients with peripherally located lesions. Based on the results of multiple randomized controlled trials and/or meta-analyses, the optimal treatment of LS-SCLC is cisplatin-etoposide (EP)-based concurrent chemoradiotherapy (45 Gy b.i.d thoracic radiotherapy) followed by prophylactic cranial irradiation (PCI: 25 Gy in ten fractions) for every patients with any objective response after chemoradiotherapy. Similarly, evidence-based treatment of ES-SCLC includes EP combination chemotherapy followed by thoracic radiotherapy and PCI in patients with any objective response. In order to achieve best results, the thoracic radiotherapy and chemotherapy should be integrated as soon as possible (preferably at first course of chemotherapy), and the overall interval between the start of chemotherapy and the completion of thoracic radiotherapy should be kept as short as possible, namely, <30 days.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosenzweig KE, Chen CP, Yom SS, Krug LM. Tumors of the lung, pleura, and mediastinum. In: Hoppe RT, Phillips TL, Roach III M, editors. Leibel and Phillips textbook of radiation oncology. Philadelphia: Saunders; 2010. p. 737–71. ISBN 978-1-4160-5897-7.

    Chapter  Google Scholar 

  2. Barnard W. The nature of the ‘oat-celled sarcoma’ of the mediastinum. J Pathol. 1926;29:241–4.

    Article  Google Scholar 

  3. Watson WL, Berg JW. Oat cell lung cancer. Cancer. 1962;15:759–68.

    Article  CAS  PubMed  Google Scholar 

  4. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18(6):1059–68.

    Article  CAS  PubMed  Google Scholar 

  5. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12(9):1096–104.

    Article  PubMed  Google Scholar 

  6. van Oosterhout AG, van de Pol M, ten Velde GP, Twijnstra A. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer. 1996;77(8):1434–41.

    Article  PubMed  Google Scholar 

  7. Yang GY, Matthews RH. Prophylactic cranial irradiation in small-cell lung cancer. Oncologist. 2000;5(4):293–8.

    Article  CAS  PubMed  Google Scholar 

  8. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973;4(2):31–42.

    CAS  Google Scholar 

  9. Greene FL, Page DL, Fleeming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. ISBN 0387952713.

    Book  Google Scholar 

  10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. ISBN 0387884408.

    Google Scholar 

  11. Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.

    Article  PubMed  Google Scholar 

  12. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18(2):338–45.

    Article  CAS  PubMed  Google Scholar 

  13. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55.

    Article  PubMed  Google Scholar 

  14. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years – an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13(5):1215–20.

    CAS  PubMed  Google Scholar 

  15. Tai P, Tonita J, Yu E, Skarsgard D. Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys. 2003;56(3):626–33.

    Article  PubMed  Google Scholar 

  16. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986;12(5):771–7.

    Article  CAS  PubMed  Google Scholar 

  17. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523–33.

    Article  CAS  PubMed  Google Scholar 

  18. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest. 1991;99(6):1425–32.

    Article  CAS  PubMed  Google Scholar 

  19. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet. 1973;2:63–5.

    Article  CAS  PubMed  Google Scholar 

  20. Miller AB, Fox W, Tall R. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet. 1969;2:501–5.

    Article  CAS  PubMed  Google Scholar 

  21. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350–7.

    Article  PubMed  Google Scholar 

  22. Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol. 2008;3(11):1267–71.

    Article  PubMed  Google Scholar 

  23. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83(12):855–61.

    Article  CAS  PubMed  Google Scholar 

  24. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2008;4, CD006849.

    PubMed  Google Scholar 

  25. Roth BJ, Johnson DH, Einhorn LH, Randolph JA, Goodlow JL, Broun GO, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10(2):282–91.

    CAS  PubMed  Google Scholar 

  26. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665–72.

    Article  CAS  PubMed  Google Scholar 

  27. Sgambato A, Casaluce F, Maione P. Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother. 2013;14(15):2019–31.

    Article  CAS  PubMed  Google Scholar 

  28. Okamoto H, Watanabe K, Kunikane H, et al. Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poorrisk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702. J Clin Oncol. 2005;23(Suppl.16):Abstract 7010.

    Google Scholar 

  29. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91.

    Article  CAS  PubMed  Google Scholar 

  30. Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038–43.

    Article  CAS  PubMed  Google Scholar 

  32. Loehrer PJ, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995;13(10):2594–9.

    CAS  PubMed  Google Scholar 

  33. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001;12(4):463–70.

    Article  CAS  PubMed  Google Scholar 

  34. Niell HB, Herndon JE, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752–9.

    Article  CAS  PubMed  Google Scholar 

  35. Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 – a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(8):2114–22.

    CAS  PubMed  Google Scholar 

  36. Sculier JP, Berghmans T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer. 1998;19(2):141–51.

    Article  CAS  PubMed  Google Scholar 

  37. Jiang J, Shi HZ, Deng JM, et al. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature. Lung Cancer. 2009;65(2):214–8.

    Article  CAS  PubMed  Google Scholar 

  38. Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther. 1996;21(2):57–63.

    Article  CAS  PubMed  Google Scholar 

  39. Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer. 2002;37(2):115–23.

    Article  CAS  PubMed  Google Scholar 

  40. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A meta-analysis of the published controlled trials. Cancer. 2005;104(12):2650–7.

    Article  CAS  PubMed  Google Scholar 

  41. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010;70(2):119–28.

    Article  PubMed  Google Scholar 

  42. Slotman BJ, Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys. 2011;79(4):998–1003.

    Article  PubMed  Google Scholar 

  43. Pignon JP, Arriagada R. Role of thoracic radiotherapy in limited stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. J Clin Oncol. 1992;10:1819–20.

    CAS  PubMed  Google Scholar 

  44. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–5.

    CAS  PubMed  Google Scholar 

  45. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11:336–44.

    CAS  PubMed  Google Scholar 

  46. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–60.

    Article  CAS  PubMed  Google Scholar 

  47. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24:1057–63.

    Article  PubMed  Google Scholar 

  48. Scotti V, Meattini I, Franzese C, et al. Radiotherapy timing in the treatment of limited-stage small cell lung cancer: the impact of thoracic and brain irradiation on survival. Tumori. 2014;100(3):289–95.

    PubMed  Google Scholar 

  49. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837–45.

    Article  PubMed  Google Scholar 

  50. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist. 2004;9(6):665–72.

    Article  PubMed  Google Scholar 

  51. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, et al. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007;33(5):461–73.

    Article  PubMed  Google Scholar 

  52. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.

    Article  CAS  PubMed  Google Scholar 

  53. Faivre-Finn C, Lorigan P, West C, Thatcher N. Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. Clin Lung Cancer. 2005;7(1):23–9.

    Article  PubMed  Google Scholar 

  54. Topkan E, Parlak C. Radiation therapy in management of small-cell lung cancer. In: Elvisegran EM, editor. Lung diseases – selected state of the art reviews. ISBN: 978-953-51-0180-2, InTech. 2012. doi:10.5772/26433.

    Google Scholar 

  55. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–24.

    Article  CAS  PubMed  Google Scholar 

  56. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681–91.

    CAS  PubMed  Google Scholar 

  57. Bogart JA, Herndon 2nd JE, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59:460–8.

    Article  CAS  PubMed  Google Scholar 

  58. Miller AA, Wang XF, Bogart JA, et al. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007;2(7):645–51.

    Article  PubMed  Google Scholar 

  59. Choi NC, Herndon 2nd JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard Daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3528–36.

    CAS  PubMed  Google Scholar 

  60. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) protocol 97–12. Int J Radiat Oncol Biol Phys. 2005;62:342–50.

    Article  CAS  PubMed  Google Scholar 

  61. Komaki R, Paulus R, Ettinger DS, et al. Phase II study of accelerated high-dose radiation therapy with concurrent chemotherapy for patients with limited small-cell lung cancer: RTOG 0239. Int J Radiat Oncol Biol Phys. 2012;83(4):e531–6.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.

    Article  PubMed  Google Scholar 

  63. Splinter TAW. Chemotherapy of small cell lung cancer (SCLC): duration of treatment. Lung Cancer. 1989;5:186–96.

    Article  Google Scholar 

  64. Bunn Jr PA, Cohen MH, Ihde DC, et al. Advances in small cell bronchogenic carcinoma: a commentary. Cancer Treat Rep. 1977;61:333–42.

    PubMed  Google Scholar 

  65. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol. 1994;12:2022–34.

    CAS  PubMed  Google Scholar 

  66. Leyvraz S, Pampallona S, Martinelli G, et al. Solid tumors working party of the European group for blood and marrow transplantation. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst. 2008;100:533–41.

    Article  CAS  PubMed  Google Scholar 

  67. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72.

    Article  CAS  PubMed  Google Scholar 

  68. Jeremic B, Shibamoto Y, Nikolic N, et al. The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): a randomized study. J Clin Oncol. 1999;17:2092–9.

    CAS  PubMed  Google Scholar 

  69. Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer. 2011;12(6):375–9.

    Article  PubMed  Google Scholar 

  70. Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer. 2011;117(23):5423–31.

    Article  PubMed  Google Scholar 

  71. Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol. 2012;102(2):234–8.

    Article  PubMed  Google Scholar 

  72. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol. 2009;4(1):37–43.

    Article  PubMed  Google Scholar 

  73. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42.

    Article  PubMed  Google Scholar 

  74. McShan DL, Fraass BA, Lichter AS. Full integration of the beam’s eye view concept into computerized treatment planning. Int J Radiat Oncol Biol Phys. 1990;18(6):1485–94.

    Article  CAS  PubMed  Google Scholar 

  75. Spoelstra FO, Senan S, Le Péchoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys. 2010;76(4):1106–13.

    Article  PubMed  Google Scholar 

  76. Pasic A, Brokx HA, Comans EF, et al. Detection and staging of preinvasive lesions and occult lung cancer in the central airways with 18F-fluorodeoxyglucose positron emission tomography: a pilot study. Clin Cancer Res. 2005;11(17):6186–9.

    Article  CAS  PubMed  Google Scholar 

  77. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–24.

    Article  CAS  PubMed  Google Scholar 

  78. Grills IS, Fitch DL, Goldstein NS, et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:334–41.

    Article  PubMed  Google Scholar 

  79. Kara M, Dizbay Sak S, Orhan D, Kavukcu S. Proximal bronchial extension with special reference to tumor localization in non-small cell lung cancer. Eur J Cardiothorac Surg. 2001;20:350–5.

    Article  CAS  PubMed  Google Scholar 

  80. Kara M, Dizbay Sak S, Orhan D, Yavuzer S. Changing patterns of lung cancer; (3/4 in.) 1.9 cm; still a safe length for bronchial resection margin? Lung Cancer. 2000;30:161–8.

    Article  CAS  PubMed  Google Scholar 

  81. Yuan S, Meng X, Yu J, et al. Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:727–34.

    Google Scholar 

  82. Kepka L, Tatro D, Moran JM, et al. Designing targets for elective nodal irradiation in lung cancer radiotherapy: a planning study. Int J Radiat Oncol Biol Phys. 2009;73:1397–403.

    Article  PubMed  Google Scholar 

  83. Liu HH, Balter P, Tutt T, et al. Assessing respiration induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:531–40.

    Article  PubMed  Google Scholar 

  84. De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006;80(3):307–12.

    Article  PubMed  Google Scholar 

  85. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010;77(2):329–36.

    Article  PubMed  Google Scholar 

  86. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):91–7.

    Article  Google Scholar 

  87. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44:1911–7.

    PubMed  Google Scholar 

  88. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.

    Article  PubMed  Google Scholar 

  89. Thomson D, Hulse P, Lorigan P, Faivre-Finn C. The role of positron emission tomography in management of small cell lung cancer. Lung Cancer. 2011;73(2):121–6.

    Article  CAS  PubMed  Google Scholar 

  90. van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008;87:49–54.

    Article  PubMed  Google Scholar 

  91. Han TJ, Kim HJ, Wu HG, et al. Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer. Jpn J Clin Oncol. 2012;42(10):948–54.

    Article  PubMed  Google Scholar 

  92. Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5(4):592–600.

    CAS  PubMed  Google Scholar 

  93. Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 1994;12(3):496–502.

    CAS  PubMed  Google Scholar 

  94. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.

    Article  PubMed  Google Scholar 

  95. Okamoto K, Okamoto I, Takezawa K, et al. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. Jpn J Clin Oncol. 2010;40(1):54–9.

    Article  PubMed  Google Scholar 

  96. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97:162–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Bork E, Ersbøll J, Dombernowsky P, et al. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol. 1991;9(9):1627–31.

    CAS  PubMed  Google Scholar 

  98. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89(8):577–80.

    Article  CAS  PubMed  Google Scholar 

  99. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet. 1996;348(9027):563–6.

    Article  CAS  PubMed  Google Scholar 

  100. Manapov F, Klöcking S, Niyazi M, et al. Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment. Strahlenther Onkol. 2012;188(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  101. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey

    Erkan Topkan MD & Berna Akkus Yildirim

  2. Department of Radiation Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey

    Ugur Selek MD

  3. Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Ugur Selek MD

Authors
  1. Erkan Topkan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berna Akkus Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ugur Selek MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erkan Topkan MD .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hacettepe University, Faculty of Med., Ankara, Turkey

    Gokhan Ozyigit

  2. Department of Radiation Oncology, Koc University, Faculty of Medicine, Istanbul, Turkey

    Ugur Selek

  3. Department of Radiation Oncology, Baskent University School of Medicine, Adana, Turkey

    Erkan Topkan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Topkan, E., Yildirim, B.A., Selek, U. (2016). Modern Radiotherapy in Limited and Extensive Stage Small-Cell Lung Cancer. In: Ozyigit, G., Selek, U., Topkan, E. (eds) Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-28761-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28761-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28759-1

  • Online ISBN: 978-3-319-28761-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation